Mayo Clinic Laboratories > Oncology > Colorectal & GI > Non-colorectal GI tumors

Non-colorectal GI tumors

Enhance diagnosis with advanced genetic analysis

Our next-generation sequencing assay for noncolorectal GI cancer assists in diagnosis, including variations in the most commonly mutated PDGFRA and KIT genes, along with NF1, BRAF, and other RAS genes. The test also includes detection of SETD2 and TP53 mutations, which have been shown to take on an aggressive clinical course. 

85%-90%

85%–90% of gastrointestinal stromal tumors are associated with mutations in the PDGRFA and KIT genes

Non-colorectal GI tumors Test menu

Non-colorectal GI tumors Non-colorectal GI tumors
Additional testing Additional testing

Non-colorectal GI tumors

Key testing

Advantages

  • Included genes are carefully selected for their association with GIST.
  • Confirms diagnosis of GIST in patients who have unusual lesions in the GI tract.
  • Pinpoints genetic mutation to inform treatment and prognosis.
View now Hematology, oncology, and hereditary test selection guide

Highlights

Comprehensive panel boosts GIST diagnosis sensitivity

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

Learn more

Additional testing

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.